Skip to main content
. Author manuscript; available in PMC: 2014 Jun 9.
Published in final edited form as: Hypertens Res. 2014 Mar 13;37(5):393–394. doi: 10.1038/hr.2014.54

Figure 1.

Figure 1

Lipid nanoparticle (LNP)-encapsulated angiotensinogen (AGT) siRNA reduced blood pressure by decreasing the liver AGT expression and circulating AGT levels in spontaneously hypertensive and normotensive rats. LNP-encapsulated AGT siRNA does not affect AGT mRNA expression in other tissues. Ang II, angiotensin II.